Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25533029 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL1401683 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL17822966 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4508237 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL13799308 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL30244596 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3625523 | 0.96 | TSHR (0.38) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL17941156 | 0.92 | TSHR (0.42) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL25182441 | 0.92 | APLNR (0.35) | ALDH1A1TDP1APLNRNR1H2CYP2D6 | |
| SCHEMBL20535618 | 0.92 | APLNR (0.35) | ALDH1A1TDP1APLNRNR1H2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4626553-A2 | TLR7 AGONISTS AND ANTIBODY-DRUG-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4562008-A1 | SUBSTITUTED PYRAZOLYL-PYRIDINYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110086946-A1 | INK COMPOSITION FOR FORMING INSULATING FILM AND INSULATING FILM FORMED FROM THE INK COMPOSITION | DIC CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2292707-A1 | INK COMPOSITION FOR FORMING AN INSULATING FILM AND AN INSULATING FILM FORMED FROM SAID INK COMPOSITION | DIC Corporation (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-10-28 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-5185433-A | Cross-linking protein compositions having two or more identical binding sites | CENTOCOR, INC. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5162505-A | Proteins modified with positively charged carriers and compositions prepared therefrom | CENTOCOR (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | BTD, HLCS, BOLA2; BOLA2B | MEN1 767/4885KMT2A 3364/4885TSHR 819/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | MEN1 3886/4885KMT2A 1067/4885TSHR 1630/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | MEN1 2692/4885KMT2A 720/4885TSHR 3114/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | MEN1 3954/4885KMT2A 1763/4885TSHR 2097/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | MEN1 2198/4885KMT2A 2161/4885TSHR 553/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | MEN1 4186/4885KMT2A 928/4885TSHR 1673/4885 |
| US-20100273839-A1 | Compounds Having Activity in Correcting Mutant-CFTR Processing and Uses Thereof | CFTR, ABCC5, ABCB11 | MEN1 3605/4885KMT2A 3993/4885TSHR 3710/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | MEN1 3186/4885KMT2A 2541/4885TSHR 1899/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | MEN1 1998/4885KMT2A 1480/4885TSHR 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.